Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 62016TN0802

    Case T-802/16: Action brought on 08 November 2016 — Endoceutics v EUIPO — Merck (FEMIBION)

    OJ C 22, 23.1.2017, p. 45–45 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    Date of document:
    08/11/2016
    Date lodged:
    08/11/2016
    Author:
    General Court
    Form:
    Judicial information
    Authentic language:
    English
    Type of procedure:
    Action for annulment
    Link
    Select all documents mentioning this document
    Instruments cited in case law:
    Link

    23.1.2017   

    EN

    Official Journal of the European Union

    C 22/45

    Action brought on 08 November 2016 — Endoceutics v EUIPO — Merck (FEMIBION)

    (Case T-802/16)

    (2017/C 022/61)

    Language in which the application was lodged: English

    Parties

    Applicant: Endoceutics, Inc. (Quebec, Canada) (represented by: M. Wahlin, lawyer)

    Defendant: European Union Intellectual Property Office (EUIPO)

    Other party to the proceedings before the Board of Appeal: Merck KGaA (Darmstadt, Germany)

    Details of the proceedings before EUIPO

    Proprietor of the trade mark at issue: Other party to the proceedings before the Board of Appeal

    Trade mark at issue: EU word mark ‘FEMIBION’ — EU trade mark No 898 924

    Procedure before EUIPO: Proceedings for a declaration of invalidity

    Contested decision: Decision of the First Board of Appeal of EUIPO of 14 July 2016 in Case R 1608/2015-1

    Form of order sought

    The applicant claims that the Court should:

    —

    annul the contested decision in part and revoke the EUTM for ‘pharmaceutical preparations for immune system support, for menopause, for menstruation, for treatment and management of pregnancy, for the prevention, treatment and management of stress, for the prevention, treatment and management of stress ill-balanced or deficient nutrition’;

    —

    order the EUTM proprietor to pay the Applicant’s costs on the appeal and with regard to the proceedings at the EUIPO.

    Plea in law

    —

    Infringement of Article 51(1)(a) of Regulation No 207/2009.
    Top